EGFR-IN-169

EGFR-IN-169 is an epidermal growth factor (EGFR) (IC50 = 5.19 μM) inhibitor form panaxadiol. EGFR-IN-169 interferes with the migration and growth of colorectal cancer cells by inhibiting EGFR-mediated RalA/EMT pathway. EGFR-IN-169 shows an IC50 value of 4.46 μM and SI of 16.92 for HCT-116 cells. EGFR-IN-169 inhibits CDKs activity, induces G0/G1 cycle arrest and inhibits migration and invasion. EGFR-IN-169 reduces mitochondrial membrane potential and induces apoptosis and ROS production. EGFR-IN-169 can be used for the research of cancer, such as colorectal cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; CDK; EGFR; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(C1=C(N2CC(O[C@@H]3C(C)(C)C(CC[C@]4(C)C5CC(O)C6[C@@]4(C)CCC6[C@@]7(C)CCCC(C)(C)O7)[C@]5(C)CC3)=O)C(Cl)=CC=C1)C2=O

Molecular Formula

C40H56ClNO6

Molecular Weight

682.33

References & Citations

[1]Tan H, et al. A novel 20 (R) dammarane panaxadiol-indole-2 ',3' -dione derivative was found to inhibit the growth and migration of colorectal cancer cells by inhibiting EGFR-mediated RalA/EMT pathway. Eur J Med Chem. 2025 Nov 15;298:118005.